Puja Aggarwal1, Katherine A Hutcheson2,3, Adam S Garden3, Frank E Mott4, Charles Lu4, Ryan P Goepfert2, Clifton D Fuller3, Stephen Y Lai2, G Brandon Gunn3, Mark S Chambers2, Erich M Sturgis5, Ehab Y Hanna2, Sanjay Shete1,6,7. 1. Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas. 6. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: This study was conducted to identify clinicodemographic risk factors for xerostomia among long-term oropharyngeal cancer (OPC) survivors. METHODS: This cross-sectional study included 906 disease-free, adult OPC survivors with a median survival duration at the time of survey of 6 years (range, 1-16 years); self-reported xerostomia scores were available for 877 participants. Study participants had completed curative treatment between January 2000 and December 2013 and responded to a survey administered from September 2015 to July 2016. The primary outcome variable was cancer patient-reported xerostomia measured with the MD Anderson Symptom Inventory Head and Neck Cancer Module. Clinicodemographic risk factors for moderate to severe xerostomia were identified via multivariable logistic regression. RESULTS: Moderate to severe xerostomia was reported by 343 of the respondents (39.1%). Female sex (odds ratio [OR], 1.82; 95% CI, 1.22-2.71; P = .003; Bayesian false-discovery probability [BFDP] = 0.568), high school or lower education (OR, 1.73; 95% CI, 1.19-2.52; P = .004; BFDP = 0.636), and current cigarette smoking at the time of survey (OR, 2.56; 95% CI, 1.19-5.47; P = .016; BFDP = 0.800) were risk factors for moderate to severe xerostomia, and bilateral intensity-modulated radiotherapy (IMRT) combined with proton therapy and ipsilateral IMRT were protective. CONCLUSIONS: In this large xerostomia study, modern radiotherapy was a protective factor, and continued cigarette smoking at the time of survey, female sex, and high school or lower education were identified as other contributing risk factors associated with moderate to severe xerostomia. Importantly, these findings need to be confirmed in prospective studies. These results can inform future research and targeted patient-centered interventions to monitor and manage radiation therapy-associated xerostomia and preserve quality of life among patients with OPC.
BACKGROUND: This study was conducted to identify clinicodemographic risk factors for xerostomia among long-term oropharyngeal cancer (OPC) survivors. METHODS: This cross-sectional study included 906 disease-free, adult OPC survivors with a median survival duration at the time of survey of 6 years (range, 1-16 years); self-reported xerostomia scores were available for 877 participants. Study participants had completed curative treatment between January 2000 and December 2013 and responded to a survey administered from September 2015 to July 2016. The primary outcome variable was cancer patient-reported xerostomia measured with the MD Anderson Symptom Inventory Head and Neck Cancer Module. Clinicodemographic risk factors for moderate to severe xerostomia were identified via multivariable logistic regression. RESULTS: Moderate to severe xerostomia was reported by 343 of the respondents (39.1%). Female sex (odds ratio [OR], 1.82; 95% CI, 1.22-2.71; P = .003; Bayesian false-discovery probability [BFDP] = 0.568), high school or lower education (OR, 1.73; 95% CI, 1.19-2.52; P = .004; BFDP = 0.636), and current cigarette smoking at the time of survey (OR, 2.56; 95% CI, 1.19-5.47; P = .016; BFDP = 0.800) were risk factors for moderate to severe xerostomia, and bilateral intensity-modulated radiotherapy (IMRT) combined with proton therapy and ipsilateral IMRT were protective. CONCLUSIONS: In this large xerostomia study, modern radiotherapy was a protective factor, and continued cigarette smoking at the time of survey, female sex, and high school or lower education were identified as other contributing risk factors associated with moderate to severe xerostomia. Importantly, these findings need to be confirmed in prospective studies. These results can inform future research and targeted patient-centered interventions to monitor and manage radiation therapy-associated xerostomia and preserve quality of life among patients with OPC.
Authors: Pètra M Braam; Judith M Roesink; Marinus A Moerland; Cornelis P J Raaijmakers; Maria Schipper; Chris H J Terhaard Journal: Int J Radiat Oncol Biol Phys Date: 2005-07-01 Impact factor: 7.038
Authors: Puja Aggarwal; Jhankruti S Zaveri; Ryan P Goepfert; Qiuling Shi; Xianglin L Du; Michael Swartz; G Brandon Gunn; Stephen Y Lai; C David Fuller; Ehab Y Hanna; David I Rosenthal; Jan S Lewin; Linda B Piller; Katherine A Hutcheson Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-11-01 Impact factor: 6.223
Authors: Mona Kamal; David I Rosenthal; Stefania Volpe; Ryan P Goepfert; Adam S Garden; Katherine A Hutcheson; Karine A Al Feghali; Mohamed Ahmed Mohamed Meheissen; Salman A Eraj; Amy E Dursteler; Bowman Williams; Joshua B Smith; Jeremy M Aymard; Joel Berends; Aubrey L White; Steven J Frank; William H Morrison; Richard Cardoso; Mark S Chambers; Erich M Sturgis; Tito R Mendoza; Charles Lu; Abdallah S R Mohamed; Clifton D Fuller; G Brandon Gunn Journal: Radiother Oncol Date: 2017-12-08 Impact factor: 6.280
Authors: Bryce B Reeve; Jianwen Cai; Hongtao Zhang; Mark C Weissler; Kathy Wisniewski; Heather Gross; Andrew F Olshan Journal: Laryngoscope Date: 2016-05-25 Impact factor: 3.325
Authors: Zeeshan Butt; Lynne I Wagner; Jennifer L Beaumont; Judith A Paice; Joshua L Straus; Amy H Peterman; George Carro; Jamie H Von Roenn; Dan Shevrin; David Cella Journal: Support Care Cancer Date: 2007-07-03 Impact factor: 3.603
Authors: Hisham Mehanna; Max Robinson; Andrew Hartley; Anthony Kong; Bernadette Foran; Tessa Fulton-Lieuw; Matthew Dalby; Pankaj Mistry; Mehmet Sen; Lorcan O'Toole; Hoda Al Booz; Karen Dyker; Rafael Moleron; Stephen Whitaker; Sinead Brennan; Audrey Cook; Matthew Griffin; Eleanor Aynsley; Martin Rolles; Emma De Winton; Andrew Chan; Devraj Srinivasan; Ioanna Nixon; Joanne Grumett; C René Leemans; Jan Buter; Julia Henderson; Kevin Harrington; Christopher McConkey; Alastair Gray; Janet Dunn Journal: Lancet Date: 2018-11-15 Impact factor: 79.321
Authors: Puja Aggarwal; Katherine A Hutcheson; Ryan P Goepfert; Adam S Garden; Naveen Garg; Frank E Mott; Clifton D Fuller; Stephen Y Lai; Gary Brandon Gunn; Mark S Chambers; Ehab Y Hanna; Erich M Sturgis; Sanjay Shete Journal: Head Neck Date: 2022-01-27 Impact factor: 3.147
Authors: Dirk Rades; Britta Warwas; Karsten Gerull; Ralph Pries; Anke Leichtle; Karl L Bruchhage; Samer G Hakim; Steven E Schild; Florian Cremers Journal: In Vivo Date: 2022 Jul-Aug Impact factor: 2.406
Authors: Puja Aggarwal; Katherine A Hutcheson; Robert Yu; Jian Wang; Clifton D Fuller; Adam S Garden; Ryan P Goepfert; Jillian Rigert; Frank E Mott; Charles Lu; Stephen Y Lai; G Brandon Gunn; Mark S Chambers; Guojun Li; Chih-Chieh Wu; Ehab Y Hanna; Erich M Sturgis; Sanjay Shete Journal: Sci Rep Date: 2022-04-22 Impact factor: 4.996